UroToday5d
Analysis of Neoadjuvant Immunotherapy and Chemotherapy for Muscle-Invasive Bladder Cancer in a National Registry.
Based on remarkable success in the metastatic/locally advanced space, Neoadjuvant Immunotherapy (NIO) is a promising novel treatment option for Muscle-Invasive Bladder Cancer (MIBC). Here, we assess ...
UroToday5d
Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease stage in penile squamous cell carcinoma.
Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited understanding of the tumor immune microenvironment (TIME). The interplay between PSCC and the immune system across disease ...
UroToday5d
A phase I dose escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear cell renal cell carcinoma.
Mutations or silencing of the von Hippel Lindau (VHL) tumor suppressor gene accumulates hypoxia-inducible factors (HIFs). HIF-2α is implicated in the oncogenesis of ~50% of patients with clear cell ...
UroToday5d
The effect of chronic kidney disease on adverse in-hospital outcomes after radical cystectomy with ileal conduit urinary diversion.
Chronic kidney disease (CKD) is frequent in bladder cancer patients undergoing radical cystectomy (RC) with ileal conduit. However, the effect of CKD on adverse in-hospital outcomes after ileal ...
UroToday5d
Quality of Life Two Years After Diagnosis of Low-Risk Prostate Cancer in the Treatment Options for Prostate Cancer Study Cohort.
Current evidence-based best practices recommend an active surveillance (AS) protocol for men with low-risk prostate cancer (LRPC). We evaluated quality of life (QOL) at baseline and at 2 years after ...
UroToday5d
Association of marginalization and PSMA-PET in prostate cancer: An analysis of the Ontario PSMA-PET Registry for Recurrent Prostate Cancer.
Prostate-specific membrane antigen positron emission tomography (PSMA PET) is a new standard for the imaging of high-risk or recurrent prostate cancer. While marginalization disparities exist for ...
UroToday5d
Assessing operative variability in robot-assisted radical prostatectomy (RARP) through AI.
Robotic-assisted radical prostatectomy (RARP) is the most commonly performed robotic procedure in urology. Using artificial intelligence (AI), surgical steps and practices can be assessed and ...
UroToday5d
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer.
The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder ...
UroToday6d
Multi-gene risk-score for prediction of clinical outcomes in treatment-naïve metastatic castrate resistant prostate cancer.
To determine the performance of a multi-gene copy number variation (MG-CNV) risk score in metastatic tissue and plasma biospecimens from treatment-naïve metastatic castrate-resistant prostate cancer ...
UroToday6d
Confirmatory Biopsy Outcomes in Patients with Grade Group 2 Prostate Cancer: Implications for Early Management.
Guideline recommendations regarding early management of grade group (GG) 2 prostate cancer with confirmatory biopsy (cBx) are not well established. Our aim was to determine which patients with GG 2 ...
UroToday7d
A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer.
Late bladder toxicity is a concern for patients receiving prostate cancer radiotherapy and negatively impacts survivors. Few risk factors are known beyond the radiation dose and volume of bladder ...
UroToday7d
The clinical value of computed tomography Hounsfield unit for diagnosing palpable inguinal lymph node metastasis in patients with penile cancer.
Computed tomography (CT) Hounsfield units (HUs) of pathologically confirmed metastatic inguinal lymph nodes (ILNs) were proved to be higher than negative ones. We designed this study to explore the ...